… by the loss of a functional protein which protects cells from disease. These disorders are difficult to treat with … adding our rescue drug to the neurons we can protect them from death. Relevance to Diagnosis/Treatment of Parkinson’s … only the patients with a strong likelihood of benefiting from the drug to be given the drug. I want to stress again …

… target neurons that synapse onto or receive synapses from a specific cell-type within the same brain region or from another, distinct brain region.  We propose to … behavior in PD. Anticipated Outcome :  We expect to emerge from this exploratory work (pilot-experiment in magnitude, …

… This grant builds upon the research from a prior grant: Feasibility of Intranasal Delivery of … obstacle. With a Rapid Response Innovation Award  from The Michael J. Fox Foundation, we showed that GDNF … brain in sufficient quantities to protect dopamine neurons from the neurotoxin, 6-hydroxydopamine (6-OHDA), a standard …

… This grant builds upon the research from a prior grant: The Role of Alpha-synuclein in the … a Pre-clinical Model Objective/Rationale: Preliminary data from our laboratory demonstrated that the protein alpha … Disease: The development of therapy for PD might evolve from a better understanding of pathogenesis of disease. Our …

… men and women. Interestingly, these effects were different from that of a nonselective estrogen agonist. Non-invasive … men and women. Interestingly, these effects were different from that of the nonselective estrogen agonist, estradiol. Overall, a selected proof of concept molecule from this series of molecules has in addition to good …

… CalDAG-GEF2 function may alleviate dyskinesias that result from L-DOPA therapy. Anticipated Outcome: We think, based on … nigra, a region that degenerates in Parkinson’s disease. From this, we will determine whether CalDAG-GEF gene-types … dyskinesia therapy. We are in the process of analyzing data from experiments that measured how deletions of the …